Loading...
•
Sep 30, 2021
Pulse Biosciences Q3 2021 Earnings Report
Revenue was generated for the first time due to the initial Controlled Launch Program participants purchasing their CellFX Systems and Cycle Units, and clinical studies were prioritized to support regulatory submissions.
Key Takeaways
Pulse Biosciences reported its Q3 2021 financial results, achieving revenue for the first time with $574 thousand. The company is focusing on clinical studies to expand the CellFX System's indications and is conducting preclinical work across other medical specialties.
Achieved third quarter 2021 revenue of $574 thousand from Controlled Launch Program participants acquiring CellFX Systems.
Onboarded 68 CellFX System Controlled Launch Program participants to date.
Completed enrollment of 150 patients in an FDA IDE approved pivotal comparison study for cutaneous non-genital warts.
Completed enrollment of 30 patients in a feasibility study for basal cell carcinoma treatment using the CellFX System.
Forward Guidance
Pulse Biosciences is focused on the Controlled Launch program and commercialization of the CellFX System, the effectiveness of the NPS technology and the CellFX System to improve patient outcomes, current and planned future clinical studies, and the market for aesthetic dermatologic procedures.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...